[논문]COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Jalkanen, Pinja; Kolehmainen, Pekka; Hä; kkinen, Hanni K.; Huttunen, Moona; Tä; htinen, Paula A.; Lundberg, Rickard; Maljanen, Sari; Reinholm, Arttu; Tauriainen, Sisko; Pakkanen, Sari H.; Levonen, Iris; Nousiainen, Arttu; Miller, Taru; Vä; limaa, Hanna; Ivaska, Lauri; Pasternack, Arja; Naves, Rauno; Ritvos, Olli; Ö; sterlund, Pamela; Kuivanen, Suvi; Smura, Teemu; Hepojoki, Jussi; Vapalahti, Olli; Lempainen, Johanna; Kakkola, Laura; Kantele, Anu; Julkunen, Ilkka

doi:10.1038/s41467-021-24285-4

[해외논문] COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants 원문보기

Nature communications, v.12 no.1, 2021년, pp.3991 -

Jalkanen, Pinja (Institute of Biomedicine, University of Turku, Turku, Finland) , Kolehmainen, Pekka (Institute of Biomedicine, University of Turku, Turku, Finland) , Häkkinen, Hanni K. (Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland) , Huttunen, Moona (Institute of Biomedicine, University of Turku, Turku, Finland) , Tähtinen, Paula A. (Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland) , Lundberg, Rickard (Institute of Biomedicine, University of Turku, Turku, Finland) , Maljanen, Sari (Institute of Biomedicine, University of Turku, Turku, Finland) , Reinholm, Arttu (Institute of Biomedicine, University of Turku, Turku, Finland) , Tauriainen, Sisko (Institute of Biomedicine, University of Turku, Turku, Finland) , Pakkanen, Sari H. (Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland) , Levonen, Iris (Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and Univer) , Nousiainen, Arttu , Miller, Taru , Välimaa, Hanna , Ivaska, Lauri , Pasternack, Arja , Naves, Rauno , Ritvos, Olli , Österlund, Pamela , Kuivanen, Suvi , Smura, Teemu , Hepojoki, Jussi , Vapalahti, Olli , Lempainen, Johanna , Kakkola, Laura , Kantele, Anu , Julkunen, Ilkka

Abstract ▼ AI-Helper

As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces spike protein-specific neutralizing antibodies associated with protective immunity. The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates. Here we show, that after the second dose, the sera of BNT162b2-vaccinated health care workers (n = 180) effectively neutralize the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant, whereas the neutralization of the B.1.351 variant is five-fold reduced. Despite the reduction, 92% of the seronegative vaccinees have a neutralization titre of >20 for the B.1.351 variant indicating some protection. The vaccinees’ neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides evidence that the second dose of the BNT162b2 vaccine induces cross-neutralization of at least some of the circulating SARS-CoV-2 variants.Emerging SARS-CoV-2 variants contain mutations in the spike protein that may affect vaccine efficacy. Here, Jalkanen et al. show, using sera from 180 BNT162b2-vaccinated health care workers, that neutralization of SARS-CoV2 variant B.1.1.7 is not affected, while neutralization of B.1.351 variant is five-fold reduced.

참고문헌 (49)

1. Dong E Du H Gardner L An interactive web-based dashboard to track COVID-19 in real time Lancet Infect. Dis. 2020 20 533 534 10.1016/S1473-3099(20)30120-1 32087114

상세보기
2. Dong Y A systematic review of SARS-CoV-2 vaccine candidates Signal Transduct. Target. Ther. 2020 5 237 10.1038/s41392-020-00352-y 33051445

상세보기
3. Okba NMA Severe acute respiratory syndrome coronavirus 2—specific antibody responses in coronavirus disease patients Emerg. Infect. Dis. 2020 26 1478 1488 10.3201/eid2607.200841 32267220

상세보기
4. Amanat F A serological assay to detect SARS-CoV-2 seroconversion in humans Nat. Med. 2020 26 1033 1036 10.1038/s41591-020-0913-5 32398876

상세보기
5. Wajnberg A Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Science 2020 370 1227 1230 10.1126/science.abd7728 33115920

상세보기
6. Deng W Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques Science 2020 369 818 823 10.1126/science.abc5343 32616673

상세보기
7. Alsoussi WB A potently neutralizing antibody protects mice against SARS-CoV-2 infection J. Immunol. 2020 205 915 922 10.4049/jimmunol.2000583 32591393

상세보기
8. Hanrath, A. T., Payne, B. A. I. & Duncan, C. J. A. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. J. Infect . 82, e29–e30 (2020).
9. Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 397 , 1459–1469 (2021).
10. Chodick, G. et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. JAMA Netw Open . 4 , e2115985 (2021).
11. Pradenas E Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes Med 2021 2 313 320 10.1016/j.medj.2021.01.005 33554155

상세보기
12. EMA. COVID-19 Vaccines: Authorised . Accessed 5th June 2021. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section .
13. Folegatti PM Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Lancet 2020 396 467 478 10.1016/S0140-6736(20)31604-4 32702298

상세보기
14. Anderson EJ Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults N. Engl. J. Med. 2020 383 2427 2438 10.1056/NEJMoa2028436 32991794

상세보기
15. Walsh EE Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates N. Engl. J. Med. 2020 383 2439 2450 10.1056/NEJMoa2027906 33053279

상세보기
16. Public Health England. Investigation of SARS-CoV-2 Variants of Concern in England https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201 (2021).
17. Tegally, H. et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Preprint at bioRxiv https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1 (2020).
18. Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2384–2361.e6 (2021).
19. Shen, X. et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29 , 529–539.e3 (2021).
20. Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological.org (2020).
21. Muik A Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Science 2021 6105 1 5
22. Cele, S., et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593, 142–146 (2021).
23. Virtanen, J. et al. Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays. Viruses 13 , 996 (2021).
24. Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2020).
25. Hou YJ SARS-CoV-2 D614G variant exhibits enhanced replication ex vivo and earlier transmission in vivo Science 2021 370 1464 1468
26. Wibmer, C. K. et al. SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27 , 622–625 (2021).
27. Lynch KL Magnitude and kinetics of anti-severe acute respiratory syndrome Coronavirus 2 antibody responses and their relationship to disease severity Clin. Infect. Dis. 2021 72 301 308 10.1093/cid/ciaa979 33501951

상세보기
28. Grossberg, A. N. et al. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients. Nat. Commun . 12 , 740 (2021).
29. Manisty C Correspondence antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals Lancet 2021 6736 2 3
30. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592 , 616–622 (2021).
31. Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021).
32. Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med . 384, 1466–1468 (2021).
33. Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med . 384, 1412–1423 (2021).
34. Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. & Leshem, E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 397, 875–877 (2021).
35. Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med . 384, 1372–1374 (2021).
36. Saadat, S. et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA 325, 1467–1469 (2021).
37. Polack FP Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine N. Engl. J. Med. 2020 383 2603 2615 10.1056/NEJMoa2034577 33301246

상세보기
38. Capetti, A. F. et al. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 vaccine. Clin. Infect. Dis . ciab214 (2021).
39. Chen WH Vaccination in the elderly: an immunological perspective Trends Immunol. 2009 30 351 359 10.1016/j.it.2009.05.002 19540808

상세보기
40. Prendecki M Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine Lancet 2021 6736 10 12
41. Sahin U COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Nature 2020 586 594 599 10.1038/s41586-020-2814-7 32998157

상세보기
42. Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci. Immunol. 6, eabi6950 (2021).
43. Jalkanen, P. et al. A combination of N and S antigens with IgA and IgG measurement strengthens the accuracy of SARS-CoV-2 serodiagnostics. J. Infect. Dis . jiab222 (2021).
44. Juuso, R. et al. A Generic, Scalable, and Rapid Time-Resolved Förster Resonance Energy Transfer-Based Assay for Antigen Detection—SARS-CoV-2 as a Proof of Concept. MBio 12, e00902–21 (2021).
45. Quick J Multiplex PCR method for MinION and illumina sequencing of Zika and other virus genomes directly from clinical samples Nat. Protoc. 2017 12 1261 1266 10.1038/nprot.2017.066 28538739

상세보기
46. Bolger AM Lohse M Usadel B Trimmomatic: a flexible trimmer for Illumina sequence data Bioinformatics 2014 30 2114 2120 10.1093/bioinformatics/btu170 24695404

상세보기
47. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at arXiv:1303.3997 (2013).
48. Li H The sequence alignment/Map format and SAMtools Bioinformatics 2009 25 2078 2079 10.1093/bioinformatics/btp352 19505943

상세보기
49. Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181 , 281–292.e6 (2020).

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증